“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

INTRODUCTION: COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gérard, Alexandre, Romani, Serena, Fresse, Audrey, Viard, Delphine, Parassol, Nadège, Granvuillemin, Aurélie, Chouchana, Laurent, Rocher, Fanny, Drici, Milou-Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204701/
https://www.ncbi.nlm.nih.gov/pubmed/32418730
http://dx.doi.org/10.1016/j.therap.2020.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204701/
https://www.ncbi.nlm.nih.gov/pubmed/32418730
http://dx.doi.org/10.1016/j.therap.2020.05.002

Ejemplares similares